Sellas Life (SLS) Climbs 12% Ahead of 'Potentially Company-Defining' Clinical Trial Result
Sellas Life Sciences bounced back by 12.26 percent on Friday to close at $13.19 apiece, as investors positioned portfolios ahead of a potentially company-defining clinical data release, supported by takeover...









